{"id":56104,"date":"2023-04-21T21:03:14","date_gmt":"2023-04-21T19:03:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/"},"modified":"2023-04-21T21:03:14","modified_gmt":"2023-04-21T19:03:14","slug":"athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/","title":{"rendered":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference"},"content":{"rendered":"
\n

CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae<\/sup> (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.<\/p>\n

<\/a><\/p>\n

\nThe American Society for Neural Therapy and Repair is a society of basic and clinical neuroscientists with a mission to better understand the way the nervous system functions and establish new procedures for its repair in response to trauma or neurodegenerative disease.<\/p>\n

\nDr. Sarah Busch, Vice President of Regenerative Medicine and Head of Business Development, has been invited to participate in this conference. On Friday, April 28th<\/sup>, she will be giving a talk in the morning titled \u201cMultiStem\u00ae Cellular Therapy for Neurological Indications\u201d during the Cell Therapies for Neural Repair session and will participate in a panel discussion later in the day titled, \u201cCareer Retention and Development of Female Neuroscientists.\u201d On April 29th<\/sup>, Dr. Busch will be co-chairing the \u201cTranslating Treatments for Neural Injury & Disease\u201d panel discussion.<\/p>\n

\n\u201cAs a company with a broad pipeline focused on treatment of neurological indications, we are excited for the opportunity to share the progress we\u2019ve made with MultiStem and engage with other experts in the field of neuroscience,\u201d commented Dr. Busch. \u201cWe are enthusiastic about the potential for collaboration and knowledge exchange that this event offers as we continue to drive forward in our mission to extend and enhance the quality of human life.”<\/p>\n

\nThe following are specific details regarding Dr. Busch’s participation in The American Society for Neural Therapy and Repair Annual Conference:<\/p>\n\n\n\n\n\n
\n

\nEvent:<\/p>\n<\/td>\n

\n

\nPlatform Presentation, \u201cMultiStem\u00ae<\/sup> Cellular Therapy for Neurological Indications\u201d<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate:<\/p>\n<\/td>\n

\n

\nFriday, April 28th, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/p>\n<\/td>\n

\n

\n9:00 a.m. ET<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/p>\n<\/td>\n

\n

\nSheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n
\n

\nEvent:<\/p>\n<\/td>\n

\n

\nPanel Discussion, \u201cCareer Retention and Development of Female Neuroscientists\u201d<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate:<\/p>\n<\/td>\n

\n

\nFriday, April 28th, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/p>\n<\/td>\n

\n

\n4:50 p.m. ET<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/p>\n<\/td>\n

\n

\nSheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n
\n

\nEvent:<\/p>\n<\/td>\n

\n

\nCo-Chair for Panel Discussion, \u201cTranslating Treatments for Neural Injury & Disease\u201d<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate:<\/p>\n<\/td>\n

\n

\nSaturday, April 29th, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/p>\n<\/td>\n

\n

\n2:30 p.m. ET<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/p>\n<\/td>\n

\n

\nSheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPlease visit https:\/\/www.asntr.org\/<\/a> for additional information and registration.<\/p>\n

\nAbout Athersys<\/b><\/p>\n

\nAthersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem\u00ae<\/sup> cell therapy product, a patented, adult-derived \u201coff-the-shelf\u201d stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com<\/a> and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com<\/a> and on our social media accounts. Follow Athersys on Twitter at www.twitter.com\/athersys<\/a>. Information that we may post about the Company on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\nAbout MultiStem\u00ae<\/sup><\/b><\/p>\n

\nMultiStem\u00ae<\/sup> (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy\u2019s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique “off-the-shelf” stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.<\/p>\n

Contacts<\/b> <\/p>\n

\nAthersys<\/b>
Ellen Gurley
\n
Manager of Corporate Communications and Investor Relations
\n
ir@athersys.com<\/a><\/p>\n

\nLHA Investor Relations<\/b>
Tirth T. Patel
\n
212-201-6614
\n
tpatel@lhai.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL. The American Society for Neural Therapy and Repair is a society of basic and clinical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56104","6":"format-standard","7":"category-industry"},"yoast_head":"\nAthersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL. The American Society for Neural Therapy and Repair is a society of basic and clinical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T19:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference\",\"datePublished\":\"2023-04-21T19:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/\"},\"wordCount\":822,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005284\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/\",\"name\":\"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005284\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"datePublished\":\"2023-04-21T19:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005284\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005284\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend","og_description":"CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL. The American Society for Neural Therapy and Repair is a society of basic and clinical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-21T19:03:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference","datePublished":"2023-04-21T19:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/"},"wordCount":822,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/","url":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/","name":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg","datePublished":"2023-04-21T19:03:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230421005284\/en\/770681\/21\/Athersys_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-participate-in-the-american-society-for-neural-therapy-and-repair-annual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56104"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56104\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}